Dutch Startup HeartEye Secures €1.7 Million to Make Hospital-Grade Heart Monitoring Portable
Netherlands, Saturday, 25 April 2026.
HeartEye transforms cardiac diagnostics by enabling 12-channel ECG recordings anywhere in under one minute, moving advanced heart monitoring from hospitals to general practices and homes. The funding will support clinical trials and AI software development as the company navigates medical device certification requirements before commercial launch.
Healthtech Innovation Addresses Critical Healthcare Gap
This development represents a significant advancement in healthtech, specifically targeting cardiovascular diagnostics technology [1]. HeartEye’s innovation addresses a fundamental challenge in healthcare delivery: the traditional requirement for specialized equipment and trained professionals to perform 12-channel electrocardiograms (ECGs), which currently represents a time-consuming and complex process [1]. The Dutch startup’s patented mobile ECG recorder brings hospital-grade cardiac diagnostic capabilities directly to general practice settings and eventually to patients’ homes, fundamentally changing how heart conditions are detected and monitored [1].
Strategic Investment Round Details and Leadership
The €1.675 million funding round was led by ROM InWest, a regional development company that specializes in supporting innovative companies through critical growth phases [1]. Notable investors joining the round include Schuberg Philis co-founder Pim Berger and Mphasis co-founder Jeroen Tas, bringing significant technology and healthcare industry expertise to HeartEye’s board [1]. Health Innovations participated as a returning investor, marking their second investment in the company and demonstrating continued confidence in HeartEye’s technology and market potential [1]. This investment timing, announced in April 2026, follows previous funding that the company received in February 2026, as mentioned during a coalition meeting focused on cardiovascular health in the Amsterdam region [2][3].
Revolutionary Technology Mechanics and Clinical Benefits
HeartEye’s fully wireless ECG recorder transforms cardiac diagnostics by enabling general practitioners, assistants, or nurses to complete a 12-channel ECG recording in under one minute [1]. The device’s user-friendly design eliminates the complexity traditionally associated with hospital-grade cardiac monitoring, making professional-quality heart diagnostics accessible outside hospital settings [1]. The technology integrates with a digital platform that allows healthcare providers to share ECG recordings with specialists for interpretation and diagnostic support, creating a collaborative approach to cardiac care [1]. This capability enables earlier detection of heart conditions, ensuring appropriate patients reach cardiologists promptly while preventing unnecessary hospital referrals for others [1].
Strategic Capital Deployment and Regulatory Pathway
The €1.675 million investment will fund several critical development phases as HeartEye navigates the complex medical device regulatory landscape [1]. Like other medical technology innovations, HeartEye must establish and certify a production process according to current Medical Device Regulation (MDR) requirements, representing a time-intensive and capital-demanding period during which clinical use remains prohibited and regular revenue generation is not possible [1]. The funding will specifically support a pivotal clinical study and continued development of the company’s artificial intelligence software capabilities [1]. Additionally, HeartEye plans to advance its digital healthcare platform and establish production capacity to meet anticipated demand following market authorization [1]. ROM InWest’s participation reflects their strategic role in supporting companies through this challenging phase, particularly noting that venture capital firms typically invest either at the prototype development stage or after CE certification and market introduction, when technological and market-related risks are substantially reduced [1].